Patents Examined by Claire M. Kaufman
  • Patent number: 6235883
    Abstract: In accordance with the present invention, there are provided fully human monoclonal antibodies against human epidermal growth factor receptor (EGF-r). Nucelotide sequences encoding and amino acid sequences comprising heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences from CDR1 through CDR3, are provided. Hybridomas expressing such immunoglobulin molecules and monoclonal antibodies are also provided.
    Type: Grant
    Filed: May 5, 1997
    Date of Patent: May 22, 2001
    Assignee: Abgenix, Inc.
    Inventors: Aya Jakobovits, Xiao-Dong Yang, Michael Gallo, Xiao-Chi Jia
  • Patent number: 6228373
    Abstract: Peptides being absorbable by the epithelial cell lining in a mammal resulting in a modulated immune response and thereby a therapeutic effect against disease, formulations containing such peptides and uses thereof.
    Type: Grant
    Filed: November 25, 1996
    Date of Patent: May 8, 2001
    Assignee: Astra Aktiebolag
    Inventors: Håkan Bergstrand, Tomas Eriksson, Magnus Lindvall, Bengt Särnstrand
  • Patent number: 6221608
    Abstract: The extracellular domain of the human erythropoietin receptor (EPO binding protein, EBP) has been expressed and overproduced in E. coli. Control of oxygen levels and pH during high density fermentation allows the production of only the protein variant with the native amino terminus. Methods disclosed permit the efficient recovery of purified EBP which quantitatively binds EPO. The active purified protein competes with membrane associated EPO receptor for binding [125I]EPO and neutralizes EPO dependent stimulation in a cell based proliferation assay. Further, the radioligand equilibrium binding constant for this interaction has been determined by immobilizing EBP on agarose gel via a free cysteine. The EBP of the present invention has many uses including the structural determination of the protein by NMR or crystallography, in drug design and discovery, and as a therapeutic. A fusion protein of EBP and an immunoglobulin heavy chain was also produced.
    Type: Grant
    Filed: January 22, 1997
    Date of Patent: April 24, 2001
    Assignee: Ortho Pharmaceutical Corporation
    Inventors: Steven A. Middleton, Dana Johnson, Frank J. McMahon, Linda S. Mulkahy, Linda K. Jolliffe
  • Patent number: 6214794
    Abstract: The present invention provides two novel polypeptides, referred to as the “N” and “C” fragments of hedgehog, or N-terminal and C-terminal fragments, respectively, which are derived after specific cleavage at a Gly↓Cys Phe site recognized by the autoproteolytic domain in the native protein. Methods of identifying compositions which affect hedgehog activity based on inhibition of cholesterol modification of hedgehog protein are described. Also provided are methods of use of the N and C fragments.
    Type: Grant
    Filed: October 7, 1996
    Date of Patent: April 10, 2001
    Assignees: The Johns Hopkins University School of Medicine, University of Washington
    Inventors: Philip A. Beachy, Randall T. Moon, Jeffrey A. Porter
  • Patent number: 6211147
    Abstract: Relaxin is useful for promoting angiogenesis and the treatment of infections or ischemic wounds where the injury results from lack of oxygen due to poor circulation.
    Type: Grant
    Filed: August 15, 1996
    Date of Patent: April 3, 2001
    Assignee: Connetics Corporation
    Inventor: Elaine Unemori
  • Patent number: 6210914
    Abstract: The present invention provides purified and isolated polynucleotides encoding IRP (Integrin Regulatory Protein) polypeptides which regulate &bgr;2 and &bgr;7 integrins and which are contemplated to participate in integrin signaling and/or recycling pathways. Also provided are methods for identifying modulators of IRP activities and methods for identifying other proteins which interact with IRP polypeptides in signaling pathways. Modulators of IRP interactions are contemplated to be useful, for example, in monitoring and treating inflammatory processes involving leukocytes.
    Type: Grant
    Filed: February 13, 1998
    Date of Patent: April 3, 2001
    Assignee: ICOS Corporation
    Inventors: Donald E. Staunton, Brian P. Lispky
  • Patent number: 6207452
    Abstract: A domain of Bcl-2 that suppresses apoptosis by allowing cell survival permits cell proliferation when mutated. The wild type domain includes amino acid residues 51 to 97 (SEQ ID NO:13) of Bcl-2. Peptides including the domain and nucleotides encoding the domain are useful in molecular screening of human tumors for the presence of mutations that allow proliferation of cells that were otherwise marked for apoptosis. The peptides are also useful to screen for proteins that play a role in the modulation of cellular proliferation.
    Type: Grant
    Filed: March 23, 1999
    Date of Patent: March 27, 2001
    Assignee: St. Louis University Health Sciences Center
    Inventor: Chinnadurai Govindaswamy
  • Patent number: 6204049
    Abstract: Compositions and methods for bioremediation of sites contaminated with chemical pollutants, wherein survival and colonization of a polluted medium by a fungal microorganism having the capacity to degrade a chemical pollutant is enhanced; and microorganisms having the capacity to degrade one or more priority pollutants.
    Type: Grant
    Filed: February 9, 1996
    Date of Patent: March 20, 2001
    Assignees: The United States of America as represented by the Secretary of Agriculture, The Administrators of Tulane Educational Fund
    Inventors: Joan Wennstrom Bennett, Adele Marie Childress, Kenneth George Wunch, William Joseph Connick, Jr.
  • Patent number: 6171800
    Abstract: CAIP polypeptide, nucleic acids, ands uses thereof. A method of evaluating a compound for the ability to bind a CAIP polypeptide; fragment or analog thereof is described.
    Type: Grant
    Filed: June 7, 1995
    Date of Patent: January 9, 2001
    Assignee: Biogen, Inc.
    Inventor: Yen-Ming Hsu
  • Patent number: 6165747
    Abstract: The present invention concerns the discovery that proteins encoded by a family of vertebrate genes, termed here hedgehog-related genes, comprise morphogenic signals produced by tissue patterning centers, and are involved in the formation of ordered spatial arrangements of differentiated tissues in vertebrates. The present invention makes available compositions and methods that can be utilized, for example to generate and/or maintain an array of different vertebrate tissue both in vitro and in vivo.
    Type: Grant
    Filed: June 5, 1995
    Date of Patent: December 26, 2000
    Assignees: President & Fellows of Harvard College, Imperial Cancer Research Technology, Ltd.
    Inventors: Philip W. Ingham, Andrew P. McMahon, Clifford J. Tabin, David A. Bumcrot, Elisa Marti-Gorostiza
  • Patent number: 6165748
    Abstract: Purified Frazzled proteins, including WG67-16, WG67-19 and WA628, and processes for producing them are disclosed. DNA molecules encoding the Frazzled proteins, including WG67-16, WG67-19 and WA628, are also disclosed. The proteins may be used in modulating the binding of Wnt genes to their receptor. They are useful in the modulation of cellular formation, growth, differentiation, proliferation and/or maintenance of a variety of adult and embryonic tissues and organs.
    Type: Grant
    Filed: July 11, 1997
    Date of Patent: December 26, 2000
    Assignees: Genetics Institute, Inc., Whitehead Institute for Biomedical Research
    Inventors: Lisa Racie, Edward Lavallie, Janet Paulsen, Hazel Sive, Benjamin Sun
  • Patent number: 6136952
    Abstract: The present invention provides an isolated polypeptide exhibiting substantially the same amino acid sequence as JAGGED, or an active fragment thereof, provided that the polypeptide does not have the amino acid sequence of SEQ ID NO:5 or SEQ ID NO:6. The invention further provides an isolated nucleic acid molecule containing a nucleotide sequence encoding substantially the same amino acid sequence as JAGGED, or an active fragment thereof, provided that the nucleotide sequence does not encode the amino acid sequence of SEQ ID NO:5 or SEQ ID NO:6. Also provided herein is a method of inhibiting differentiation of hematopoietic progenitor cells by contacting the progenitor cells with an isolated JAGGED polypeptide, or active fragment thereof. The invention additionally provides a method of diagnosing Alagille Syndrome in an individual. The method consists of detecting an Alagille Syndrome disease-associated mutation linked to a JAGGED locus.
    Type: Grant
    Filed: June 25, 1997
    Date of Patent: October 24, 2000
    Assignee: University of Washington
    Inventors: Linheng Li, Leroy Hood
  • Patent number: 6136958
    Abstract: Novel vertebrate homologues of Smoothened, including human and rat Smoothened, are provided. Compositions including vertebrate Smoothened chimeras, nucleic acid encoding vertebrate Smoothened, and antibodies to vertebrate Smoothened, are also provided.
    Type: Grant
    Filed: September 30, 1997
    Date of Patent: October 24, 2000
    Assignee: Genentech, Inc.
    Inventors: Frederic J. de Sauvage, Arnon Rosenthal, Donna M. Stone
  • Patent number: 6130058
    Abstract: The present invention relates to a stably co-transfected eukaryotic cell line that expresses an N-methyl-D-aspartate (NMDA) receptor, particularly a human NMDA receptor, which receptor comprises at least one R1 subunit isoform, or at least one R1 subunit isoform and one or two R2 subunits. Additionally, the cell line can be used to design and develop NMDA receptor subtype-selective compounds. The invention also relates to cloning of novel cDNA sequences encoding the human NMDAR 2A subunit and various isoforms of the human NMDA R1 subunit.
    Type: Grant
    Filed: May 10, 1995
    Date of Patent: October 10, 2000
    Assignee: Merck Sharpe & Dohme Ltd.
    Inventors: Beatrice Le Bourdelles, Janice Ann Myers, Paul John Whiting
  • Patent number: 6117975
    Abstract: Genes encoding melanocortin receptors have been identified, isolated, cloned and localized to their chromosomal positions. These genes have been used to transfect mammalian cells lacking endogenous melanocortin receptors to induce expression. Additionally, melanocortin receptor binding, secondary signalling, and tissue distribution has been characterized. The genes and their gene products may therefore be used to to provide therapeutic vehicles for the treatment of processes involving the function of melanocortin receptors.
    Type: Grant
    Filed: July 23, 1996
    Date of Patent: September 12, 2000
    Assignee: The Regents of the University of Michigan
    Inventors: Tadataka Yamada, Ira Gantz
  • Patent number: 6114306
    Abstract: Pyruvate kinase deficiency is a blood disease characterized by hemolytic anemia. PCR analysis of cDNA leukocytic extracts of patients with hereditary pyruvate kinase deficiency anemia revealed two overexpressed markers when compared to extracts from healthy individuals. These two markers, proposed as human markers A and B and associated with hereditary hemolytic anemia, have been cloned (HUMDNAMA and HUMDNAMB, Gen Bank Association numbers M64700 and M64701). Our attention has focused on human DNA marker B, a 451 bp open-reading frame. The marker has been cloned in the bacteria vector pGEX-2TK and the expressed protein, called HMF (hemolytic anemia related factor), has been tested for biological activity. It has been observed that the HMF-glutathione transferase fusion protein, added to freshly prepared leukocytes cultures, has an immediate cytotoxic effect and a delayed lymphoblastic effect. The lymphoblastic effect is greatly enhanced when erythrocytes are added to the leucocytes.
    Type: Grant
    Filed: April 15, 1997
    Date of Patent: September 5, 2000
    Assignee: Universite de Sherbrooke
    Inventors: Eveline de Medicis, Andre Larochelle
  • Patent number: 6103524
    Abstract: This invention describes a novel human glutamate receptor, designated mGluR6. This invention also encompasses nucleic acids encoding this receptor, or a fragment thereof, as well as methods employing this receptor and the nucleic acid compounds.
    Type: Grant
    Filed: August 30, 1998
    Date of Patent: August 15, 2000
    Assignee: Eli Lilly and Company
    Inventors: Rama Moorthy Belagaje, Su Wu
  • Patent number: 6100048
    Abstract: The present invention provides recombinant expression constructs comprising nucleic acid encoding mammalian melanocortin receptors, and mammalian cells into which said recombinant expression constructs have been introduced that express functional mammalian melanocortin receptors. The invention provides a panel of such transformed mammalian cells expressing melanocortin receptors for screening compounds for receptor agonist and antagonist activity. The invention also provides methods for using such panels of melanocortin receptor-expressing mammalian cells to specifically detect and identify agonists and antagonists for each melanocortin receptor, as well as patterns of agonist and antagonist activity of said compounds for the class of melanocortin receptors. Such screening methods provide a means for identifying compounds with patterns of melanocortin agonist and antagonist activity which are associated with the capacity to influence or modify metabolism and behavior, particularly feeding behavior.
    Type: Grant
    Filed: September 4, 1996
    Date of Patent: August 8, 2000
    Assignee: Oregon Health Sciences University
    Inventors: Roger D. Cone, Wei Fan, Bruce A. Boston, Robert A. Kesterton, Dongsi Lu, Wenbiao Chen
  • Patent number: 6099841
    Abstract: Hepatocyte growth factor (HGF) receptor agonists are provided. The HGF receptor agonists include HGF receptor antibodies and fragments thereof. The HGF receptor agonists can be employed to substantially enhance HGF receptor activation. The HGF receptor agonists may be included in pharmaceutical compositions, articles of manufacture, or kits. Methods of treatment and diagnosis using the HGF receptor agonists are also provided.
    Type: Grant
    Filed: June 27, 1997
    Date of Patent: August 8, 2000
    Assignee: Genentech, Inc.
    Inventors: Kenneth J. Hillan, Ralph H. Schwall, Kelly H. Tabor
  • Patent number: 6100071
    Abstract: The present invention is directed to novel chimeric VEGF receptor proteins comprising amino acid sequences derived from the vascular endothelial growth factor (VEGF) receptors flt-1 and KDR, including the murine homologue to the human KDR receptor FLK-1, wherein said chimeric VEGF receptor proteins bind to VEGF and antagonize the endothelial cell proliferative and angiogenic activity thereof. The present invention is also directed to nucleic acids and expression vectors encoding these chimeric VEGF receptor proteins, host cells harboring such expression vectors, pharmaceutically acceptable compositions comprising such proteins, methods of preparing such proteins and to methods utilizing such proteins for the treatment of conditions associated with undesired vascularization.
    Type: Grant
    Filed: May 7, 1996
    Date of Patent: August 8, 2000
    Assignee: Genentech, Inc.
    Inventors: Terri Lynn Davis-Smyth, Helen Hsifei Chen, Leonard Presta, Napoleone Ferrara